RESUMO
This two-day workshop, co-sponsored by NICEATM and IABS-NA, brought together over 60 international scientists from government, academia, and industry to advance alternative methods for human and veterinary Rabies Virus Vaccine (RVV) potency testing. On day one, workshop presentations focused on regulatory perspectives related to in vitro potency testing, including recent additions to the European Pharmacopoeia (5.2.14) that provide a scientific rationale for why in vivo methods may be less suitable for vaccine quality control than appropriately designed in vitro methods. Further presentations reviewed the role of the consistency approach to manufacturing and vaccine batch comparison to provide supportive data for the substitution of existing animal-based methods with in vitro assays. In addition, updates from research programs evaluating and validating RVV glycoprotein (G) quantitation by ELISA as an in vitro potency test were presented. On the second day, RVV stakeholders participated in separate human and veterinary vaccine discussion groups focused on identifying potential obstacles or additional requirements for successful implementation of non-animal alternatives to the in vivo potency test. Workshop outcomes and proposed follow up activities are discussed herein.
Assuntos
Vacina Antirrábica/uso terapêutico , Vírus da Raiva/imunologia , Raiva/prevenção & controle , Potência de Vacina , Animais , Disciplinas das Ciências Biológicas , Educação , Humanos , Controle de Qualidade , Raiva/imunologia , Raiva/patologia , Vacina Antirrábica/imunologia , Sociedades CientíficasRESUMO
Potency testing of most human and veterinary rabies vaccines requires vaccination of mice followed by a challenge test using an intracerebral injection of live rabies virus. NICEATM, ICCVAM, and their international partners organized a workshop to review the availability and validation status of alternative methods that might reduce, refine, or replace the use of animals for rabies vaccine potency testing, and to identify research and development efforts to further advance alternative methods. Workshop participants agreed that general anesthesia should be used for intracerebral virus injections and that humane endpoints should be used routinely as the basis for euthanizing animals when conducting the mouse rabies challenge test. Workshop participants recommended as a near-term priority replacement of the mouse challenge with a test validated to ensure potency, such as the mouse antibody serum neutralization test for adjuvanted veterinary rabies vaccines for which an international collaborative study was recently completed. The workshop recommended that an in vitro antigen quantification test should be a high priority for product-specific validation of human and non-adjuvanted veterinary rabies vaccines. Finally, workshop participants recommended greater international cooperation to expedite development, validation, regulatory acceptance, and implementation of alternative test methods for rabies vaccine potency testing.
Assuntos
Alternativas aos Testes com Animais , Avaliação Pré-Clínica de Medicamentos/métodos , Avaliação Pré-Clínica de Medicamentos/tendências , Vacina Antirrábica , Alternativas aos Testes com Animais/métodos , Alternativas aos Testes com Animais/organização & administração , Animais , Educação/organização & administração , Educação em Veterinária/métodos , Planejamento em Saúde/tendências , Humanos , Cooperação Internacional , Camundongos , Raiva/imunologia , Raiva/veterinária , Vacina Antirrábica/farmacologia , Vacina Antirrábica/normas , Vacina Antirrábica/uso terapêutico , Pesquisa/tendências , Relatório de Pesquisa , Ciência/tendências , Vacinação/métodos , Vacinação/veterináriaAssuntos
Doenças do Cão/prevenção & controle , Vigilância de Produtos Comercializados , Vacina Antirrábica/efeitos adversos , Vacina Antirrábica/imunologia , Raiva/veterinária , Vacinação/veterinária , Animais , Cães , Feminino , Masculino , Raiva/prevenção & controle , Segurança , Resultado do Tratamento , Estados UnidosRESUMO
Rabies is an incurable zoonotic disease caused by rabies virus, a member of the rhabdovirus family. It is transmitted through the bite of an infected animal. Control methods, including oral rabies vaccination (ORV) programs, have led to a reduction in the spread and prevalence of the disease in wildlife. This study evaluated the stability of RABORAL, a recombinant vaccinia virus vaccine that is used in oral rabies vaccination programs. The vaccine was studied in various field microenvironments in order to describe its viability and facilitate effective baiting strategies. Field microenvironments influenced the stability of this vaccine in this study. This study emphasizes the importance of understanding how vaccines perform under varying field conditions in order to plan effective baiting strategies.